BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17203106)

  • 41. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
    Imagawa Y; Satake K; Kato Y; Tahara H; Tsukuda M
    Auris Nasus Larynx; 2004 Sep; 31(3):239-45. PubMed ID: 15364358
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth.
    Tamura T; Nishi T; Goto T; Takeshima H; Ushio Y; Sakata T
    Anticancer Res; 2003; 23(2B):1173-9. PubMed ID: 12820368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy.
    Sanches R; Kuiper M; Penault-Llorca F; Aunoble B; D'Incan C; Bignon YJ
    Cancer Gene Ther; 2000 May; 7(5):707-20. PubMed ID: 10830718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma.
    Hu P; Hu HD; Chen M; Peng ML; Tang L; Tang KF; Matsui M; Belladonna ML; Yoshimoto T; Zhang DZ; Xiang R; Ren H
    Mol Immunol; 2009 May; 46(8-9):1654-62. PubMed ID: 19299021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.
    Hull GW; Mccurdy MA; Nasu Y; Bangma CH; Yang G; Shimura S; Lee HM; Wang J; Albani J; Ebara S; Sato T; Timme TL; Thompson TC
    Clin Cancer Res; 2000 Oct; 6(10):4101-9. PubMed ID: 11051263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
    Pajtasz-Piasecka E; Rossowska J; Szyda A; Krawczenko A; Dus D
    Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Augmented antitumor activity of a secondary lymphoid-tissue chemokine (SLC)-interleukin (IL) 2 fusion protein in mouse.
    Nakahara K; Sakata T
    J Gene Med; 2003 Jun; 5(6):463-71. PubMed ID: 12797111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
    Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
    J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.
    McBride WH; Thacker JD; Comora S; Economou JS; Kelley D; Hogge D; Dubinett SM; Dougherty GJ
    Cancer Res; 1992 Jul; 52(14):3931-7. PubMed ID: 1617669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma.
    Leng J; Zhang L; Yao H; Cao X
    Chin Med J (Engl); 2003 Oct; 116(10):1475-9. PubMed ID: 14570604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.
    Mazzolini G; Qian C; Xie X; Sun Y; Lasarte JJ; Drozdzik M; Prieto J
    Cancer Gene Ther; 1999; 6(6):514-22. PubMed ID: 10608348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model.
    Yamashita YI; Shimada M; Hasegawa H; Minagawa R; Rikimaru T; Hamatsu T; Tanaka S; Shirabe K; Miyazaki JI; Sugimachi K
    Cancer Res; 2001 Feb; 61(3):1005-12. PubMed ID: 11221826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.
    Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y
    Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer.
    Loskog A; Björkland A; Brown MP; Korsgren O; Malmström PU; Tötterman TH
    J Urol; 2001 Sep; 166(3):1093-7. PubMed ID: 11490305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
    Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
    J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
    Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
    Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity.
    Maheshwari A; Han S; Mahato RI; Kim SW
    Gene Ther; 2002 Aug; 9(16):1075-84. PubMed ID: 12140735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer.
    Paul S; Regulier E; Poitevin Y; Hormann H; Acres RB
    Cancer Immunol Immunother; 2002 Dec; 51(11-12):645-54. PubMed ID: 12439610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
    Sivanandham M; Stavropoulos CI; Kim EM; Mancke B; Wallack MK
    Cancer Immunol Immunother; 2002 Apr; 51(2):63-71. PubMed ID: 11904730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.